IP Library › Granted Patent US 12678478
Granted Patent B2
US 12678478 · App. 17/916,337 · Granted Jul 14, 2026

Compositions and methods for treating dysregulated wound healing

Inventor: Arjun Deb (Los Angeles, CA)
Assignee: The Regents of the University of California
A61K38/12A61P17/02A61P19/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678478
App. No.
17/916,337
Granted
Jul 14, 2026
Kind
B2
Abstract

The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

Claims (17)

1 . A method of treating a subject with classic Ehlers Danlos syndrome (EDS), comprising administering cilengitide to the subject.

2 . The method of claim 1 , wherein the subject has dysregulated wound healing.

3 . The method of claim 1 , wherein the subject has acute myocardial infarction.

4 . The method of claim 1 , wherein the subject suffers from exaggerated and aberrant wound healing with increased scarring following injury trauma or surgery.

5 . The method of claim 1 , wherein the subject has a mutation in Col5a1.

6 . The method of claim 5 , wherein the mutation is haploinsufficiency.

7 . The method of claim 1 , wherein the subject exhibits up-regulation of αvβ3 integrin receptor.

8 . The method of claim 1 , wherein cilengitide is administered 1 to 30 days prior to a surgery or childbirth.

9 . The method of claim 8 , wherein cilengitide is administered 7 days prior to the surgery or childbirth.

10 . The method of claim 8 , wherein cilengitide is administered daily.

11 . The method of claim 8 , wherein cilengitide is administered after the surgery or childbirth until healing of wound has occurred.

12 . The method of claim 8 , wherein cilengitide is administered 1 to 30 days after the surgery or childbirth.

13 . The method of claim 8 , wherein cilengitide is administered 1 to 7 days after the surgery or childbirth.

14 . The method of claim 8 , wherein the cilengitide is administered daily.

15 . The method of claim 1 , wherein cilengitide is administered after an acute trauma until healing of wound has occurred.

16 . The method of claim 1 , wherein cilengitide is administered 1 to 30 days after the acute trauma, 1 to 14 days after the acute trauma, or 1 to 7 days after the acute trauma.

17 . The method of claim 15 , wherein cilengitide is administered daily.